Complement Activation in 22q11.2 Deletion Syndrome
Authors:
Open Access
- 9 March 2020
- journal article
- research article
- Published by Springer Nature in Journal of Clinical Immunology
- Vol. 40 (3) , 515-523
Abstract
The 22q11.2 deletion syndrome (22q11.2 del), also known as DiGeorge syndrome, is a genetic disorder with an estimated incidence of 1:3000 to 1:6000 births. These patients may suffer from affection of many organ systems with cardiac malformations, immunodeficiency, hypoparathyroidism, autoimmunity, palate anomalies, and psychiatric disorders being the most frequent. The importance of the complement system in 22q11.2 del has not been investigated. The objective of this study was to evaluate the complement system in relation to clinical and immunological parameters in patients. A national cohort of patients (n = 69) with a proven heterozygous deletion of chromosome 22q11.2 and a group of age and sex matched controls (n = 56) were studied. Functional capacity of the classical, lectin, and alternative pathways of the complement system as well as complement activation products C3bc and terminal complement complex (TCC) were accessed and correlated to clinical features. All patients in our study had normal complement activation in both classical and alternative pathways. The frequency of mannose-binding lectin deficiency was comparable to the normal population. The patients had significantly raised plasma levels of C3bc and a slight, but not significant, increase in TCC compared with controls. This increase was associated with the presence of psychiatric disorders in patients. The present study shows no complement deficiencies in 22q11.2 deletion syndrome. On the contrary, there are signs of increased complement activation in these patients. Complement activation is particularly associated with the presence of psychiatric disorders.Keywords
Funding Information
- Helse Sør-Øst RHF (2011063)
This publication has 44 references indexed in Scilit:
- The complement system is dysfunctional in metabolic disease: Evidences in plasma and adipose tissue from obese and insulin resistant subjectsSeminars in Cell & Developmental Biology, 2019
- Obesity in adults with 22q11.2 deletion syndromeGenetics in Medicine, 2016
- Complement in disease: a defence system turning offensiveNature Reviews Nephrology, 2016
- 22q11.2 deletion syndromeNature Reviews Disease Primers, 2015
- Immunodeficiency in DiGeorge Syndrome and Options for Treating Cases with Complete AthymiaFrontiers in Immunology, 2013
- Chromosome 22q11.2 Deletion Syndrome (DiGeorge Syndrome/Velocardiofacial Syndrome)Medicine, 2011
- Age-dependent clinical problems in a Norwegian national survey of patients with the 22q11.2 deletion syndromeEuropean Journal of Pediatrics, 2010
- Complement analysis in the 21st centuryMolecular Immunology, 2007
- Incidence and prevalence of the 22q11 deletion syndrome: a population-based study in Western SwedenArchives of Disease in Childhood, 2004
- Characterization of a Monoclonal Antibody MoAb bH6 Reacting with a Neoepitope of Human C3 Expressed on C3b, iC3b, and C3cScandinavian Journal of Immunology, 1988